Herpes Simplex Infections - Pipeline Review, H2 2015

Date: September 23, 2015
Pages: 185
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H5A8068832CEN
Leaflet:

Download PDF Leaflet

Herpes Simplex Infections - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Herpes Simplex Infections - Pipeline Review, H2 2015’, provides an overview of the Herpes Simplex Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Herpes Simplex Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Herpes Simplex Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Herpes Simplex Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Herpes Simplex Infections Overview
Therapeutics Development
Pipeline Products for Herpes Simplex Infections - Overview
Pipeline Products for Herpes Simplex Infections - Comparative Analysis
Herpes Simplex Infections - Therapeutics under Development by Companies
Herpes Simplex Infections - Therapeutics under Investigation by Universities/Institutes
Herpes Simplex Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Herpes Simplex Infections - Products under Development by Companies
Herpes Simplex Infections - Products under Investigation by Universities/Institutes
Herpes Simplex Infections - Companies Involved in Therapeutics Development
3-V BIOSCIENCES, INC.
Adamis Pharmaceuticals Corporation
Admedus Ltd
AiCuris GmbH & Co. KG
Astellas Pharma Inc.
Beech Tree Labs, Inc.
CEL-SCI Corporation
Chimerix, Inc.
Epiphany Biosciences, Inc.
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
GenVec, Inc.
Immune Design Corp.
Immunovaccine, Inc.
JN-International Medical Corporation
Microbiotix, Inc.
Mymetics Corporation
NanoBio Corporation
NanoViricides, Inc.
Onxeo SA
Oryzon Genomics S.A.
Osel Inc.
PaxVax
Peregrine Pharmaceuticals, Inc.
Profectus BioSciences, Inc.
Romark Laboratories, L.C.
Sanofi
Sanofi Pasteur SA
Shulov Innovative Science Ltd.
Spider Biotech
Starpharma Holdings Limited
Vaccibody AS
Vaxart, Inc.
Vical Incorporated
Vironova AB
ViroStatics, srl
Herpes Simplex Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(celecoxib + famciclovir) - Drug Profile
acyclovir - Drug Profile
acyclovir - Drug Profile
amenamevir - Drug Profile
Aspidasept - Drug Profile
astodrimer - Drug Profile
Biologic for Infectious Disease - Drug Profile
brincidofovir - Drug Profile
BTL-TMLHSV - Drug Profile
C-31G - Drug Profile
CEL-1000 - Drug Profile
G-103 - Drug Profile
GEN-002 - Drug Profile
GEN-003 - Drug Profile
genital herpes vaccine [HSV-2] - Drug Profile
GV-2207 - Drug Profile
Herpecide - Drug Profile
herpes simplex virus [serotype 2] vaccine - Drug Profile
herpes simplex virus [type 1, 2] vaccine - Drug Profile
herpes simplex virus [type 1] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
herpes simplex virus [type 2] vaccine - Drug Profile
HSV vaccine - Drug Profile
HSV-529 - Drug Profile
MB-66 - Drug Profile
MBX-2168 - Drug Profile
Monoclonal Antibodies for HIV and Herpes Simplex Infections - Drug Profile
Monoclonal Antibody for Herpes Simplex Infections - Drug Profile
Monoclonal Antibody for Herpes Simplex Infections - Drug Profile
Peptide for HIV and HSV Infections - Drug Profile
PGN-632 - Drug Profile
pritelivir - Drug Profile
RC-100b - Drug Profile
RKP-00156 - Drug Profile
SB-105 - Drug Profile
SB-105A10 - Drug Profile
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV and HSV Infections - Drug Profile
Small Molecule to Inhibit LSD-1 for HSV - Drug Profile
Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections - Drug Profile
Small Molecules for Viral Infections - Drug Profile
Small Molecules to Inhibit Fatty Acid Synthase for Viral Infections - Drug Profile
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
Synthetic Peptides for Oncology and Infectious Disease - Drug Profile
Synthetic Peptides for Viral Infections - Drug Profile
Teg-379 - Drug Profile
UB-621 - Drug Profile
valomaciclovir stearate - Drug Profile
VCLHB-01 - Drug Profile
VCLHM-01 - Drug Profile
VN-180 - Drug Profile
ZEP-3 - Drug Profile
Herpes Simplex Infections - Recent Pipeline Updates
Herpes Simplex Infections - Dormant Projects
Herpes Simplex Infections - Discontinued Products
Herpes Simplex Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Herpes Simplex Infections, H2 2015
Number of Products under Development for Herpes Simplex Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Herpes Simplex Infections - Pipeline by 3-V Biosciences, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015
Herpes Simplex Infections - Pipeline by Admedus Ltd, H2 2015
Herpes Simplex Infections - Pipeline by AiCuris GmbH & Co. KG, H2 2015
Herpes Simplex Infections - Pipeline by Astellas Pharma Inc., H2 2015
Herpes Simplex Infections - Pipeline by Beech Tree Labs, Inc., H2 2015
Herpes Simplex Infections - Pipeline by CEL-SCI Corporation, H2 2015
Herpes Simplex Infections - Pipeline by Chimerix, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Epiphany Biosciences, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Herpes Simplex Infections - Pipeline by Genocea Biosciences, Inc., H2 2015
Herpes Simplex Infections - Pipeline by GenVec, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Immune Design Corp., H2 2015
Herpes Simplex Infections - Pipeline by Immunovaccine, Inc., H2 2015
Herpes Simplex Infections - Pipeline by JN-International Medical Corporation, H2 2015
Herpes Simplex Infections - Pipeline by Microbiotix, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Mymetics Corporation, H2 2015
Herpes Simplex Infections - Pipeline by NanoBio Corporation, H2 2015
Herpes Simplex Infections - Pipeline by NanoViricides, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Onxeo SA, H2 2015
Herpes Simplex Infections - Pipeline by Oryzon Genomics S.A., H2 2015
Herpes Simplex Infections - Pipeline by Osel Inc., H2 2015
Herpes Simplex Infections - Pipeline by PaxVax, H2 2015
Herpes Simplex Infections - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Profectus BioSciences, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Romark Laboratories, L.C., H2 2015
Herpes Simplex Infections - Pipeline by Sanofi, H2 2015
Herpes Simplex Infections - Pipeline by Sanofi Pasteur SA, H2 2015
Herpes Simplex Infections - Pipeline by Shulov Innovative Science Ltd., H2 2015
Herpes Simplex Infections - Pipeline by Spider Biotech, H2 2015
Herpes Simplex Infections - Pipeline by Starpharma Holdings Limited, H2 2015
Herpes Simplex Infections - Pipeline by Vaccibody AS, H2 2015
Herpes Simplex Infections - Pipeline by Vaxart, Inc., H2 2015
Herpes Simplex Infections - Pipeline by Vical Incorporated, H2 2015
Herpes Simplex Infections - Pipeline by Vironova AB, H2 2015
Herpes Simplex Infections - Pipeline by ViroStatics, srl, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Herpes Simplex Infections Therapeutics - Recent Pipeline Updates, H2 2015
Herpes Simplex Infections - Dormant Projects, H2 2015
Herpes Simplex Infections - Dormant Projects (Contd..1), H2 2015
Herpes Simplex Infections - Dormant Projects (Contd..2), H2 2015
Herpes Simplex Infections - Dormant Projects (Contd..3), H2 2015
Herpes Simplex Infections - Dormant Projects (Contd..4), H2 2015
Herpes Simplex Infections - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Herpes Simplex Infections, H2 2015
Number of Products under Development for Herpes Simplex Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

3-V Biosciences, Inc.
Adamis Pharmaceuticals Corporation
Admedus Ltd
AiCuris GmbH & Co. KG
Astellas Pharma Inc.
Beech Tree Labs, Inc.
CEL-SCI Corporation
Chimerix, Inc.
Epiphany Biosciences, Inc.
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
GenVec, Inc.
Immune Design Corp.
Immunovaccine, Inc.
JN-International Medical Corporation
Microbiotix, Inc.
Mymetics Corporation
NanoBio Corporation
NanoViricides, Inc.
Onxeo SA
Oryzon Genomics S.A.
Osel Inc.
PaxVax
Peregrine Pharmaceuticals, Inc.
Profectus BioSciences, Inc.
Romark Laboratories, L.C.
Sanofi
Sanofi Pasteur SA
Shulov Innovative Science Ltd.
Spider Biotech
Starpharma Holdings Limited
Vaccibody AS
Vaxart, Inc.
Vical Incorporated
Vironova AB
ViroStatics, srl
Skip to top


HIV-1 Infection - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 406 pages
Urinary Tract Infections - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 139 pages

Ask Your Question

Herpes Simplex Infections - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: